{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:11:51Z","timestamp":1753182711818},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,19]]},"DOI":"10.7759\/cureus.49051","type":"journal-article","created":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T17:09:00Z","timestamp":1700413740000},"source":"Crossref","is-referenced-by-count":1,"title":["Skin Rash as a Side Effect of Bortezomib: A Case Report"],"prefix":"10.7759","author":[{"given":"Marah","family":"Khaldy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Amar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munther","family":"Alshyoukhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Arafat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-019-0269-9","article-title":"Bortezomib for the treatment of hematologic malignancies: 15 years later","volume":"19","author":"Robak P","year":"2019","unstructured":"Robak P, Robak T. Bortezomib for the treatment of hematologic malignancies: 15 years later. Drugs R D. 2019, 19:73-92. 10.1007\/s40268-019-0269-9","journal-title":"Drugs R D"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000111513","article-title":"Bortezomib-induced skin eruption","volume":"216","author":"Sanchez-Politta S","year":"2008","unstructured":"Sanchez-Politta S, Favet L, Kerl K, Dietrich PY, Piguet V. Bortezomib-induced skin eruption. Dermatology. 2008, 216:156-8. 10.1159\/000111513","journal-title":"Dermatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.173","article-title":"Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma","volume":"31","author":"Richardson PG","year":"2017","unstructured":"Richardson PG, Hofmeister CC, Raje NS, et al.. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2017, 31:2695-701. 10.1038\/leu.2017.173","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen CB","year":"2018","unstructured":"Chen CB, Wu MY, Ng CY, et al.. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018, 10:1259-73. 10.2147\/CMAR.S163391","journal-title":"Cancer Manag Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.08.023","article-title":"Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma","volume":"33","author":"Hattori N","year":"2009","unstructured":"Hattori N, Adachi D, Nakashima H, Saito B, Nakamaki T, Tomoyasu S. Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma. Leuk Res. 2009, 33:574-7. 10.1016\/j.leukres.2008.08.023","journal-title":"Leuk Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05636.x","article-title":"Bortezomib-induced Sweet syndrome","volume":"131","author":"Knoops L","year":"2005","unstructured":"Knoops L, Jacquemain A, Tennstedt D, Theate I, Ferrant A, Van den Neste E. Bortezomib-induced Sweet syndrome. Br J Haematol. 2005, 131:142. 10.1111\/j.1365-2141.2005.05636.x","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson PG","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, et al.. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003, 348:2609-17. 10.1056\/NEJMoa030288","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.030","article-title":"Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma","volume":"55","author":"Wu KL","year":"2006","unstructured":"Wu KL, Heule F, Lam K, Sonneveld P. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. J Am Acad Dermatol. 2006, 55:897-900. 10.1016\/j.jaad.2006.06.030","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06201.x","article-title":"Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: A possible surrogate marker of response?","volume":"134","author":"Gerecitano J","year":"2006","unstructured":"Gerecitano J, Goy A, Wright J, et al.. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: A possible surrogate marker of response?. Br J Haematol. 2006, 134:391-8. 10.1111\/j.1365-2141.2006.06201.x","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.9092","article-title":"Risk of skin rash with the proteasome inhibitor bortezomib: Updated systematic review and meta-analysis","volume":"30","author":"Case EC","year":"2012","unstructured":"Case EC, Wu S, Gerecitano JF, Lacouture ME. Risk of skin rash with the proteasome inhibitor bortezomib: Updated systematic review and meta-analysis. J Clin Oncol. 2012, 30:9092. 10.1200\/jco.2012.30.15_suppl.9092","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.5070\/D30CV3T3F4","article-title":"Bortezomib-induced cutaneous lesions in multiple myeloma patients: A case report","volume":"14","author":"Rodr\u00edguez-Mart\u00edn M","year":"2008","unstructured":"Rodr\u00edguez-Mart\u00edn M, S\u00e1ez-Rodr\u00edguez M, Garc\u00eda-Bust\u00ednduy M, Mart\u00edn-Herrera A, Noda-Cabrera A. Bortezomib-induced cutaneous lesions in multiple myeloma patients: A case report. Dermatol Online J. 2008, 14:14.","journal-title":"Dermatol Online J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/201214-skin-rash-as-a-side-effect-of-bortezomib-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:32Z","timestamp":1707508352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/201214-skin-rash-as-a-side-effect-of-bortezomib-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,19]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.49051","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,19]]}}}